Articles

Poll

Podcasts

Slideshows

Videos

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

In our recap for Q2 in dermatology, we spotlight clinical trial findings, recent updates, and advancements in different disease states.

Q2 2025 Recap: Dermatology News and Updates

In the BE BRIGHT trial presented at SDPA 2025, patients receiving continuous bimekizumab therapy maintained high PASI 90 and PASI 100 response rates over 5 years.

Bimekizumab Shows Sustained 5-Year Efficacy, Safety in Plaque Psoriasis Patients 

At SDPA 2025, Gordon presented on the future of dermatology, discussing current drugs being evaluated for atopic dermatitis, psoriasis, and hidradenitis suppurativa.

Promising Drugs in the Pipeline for Atopic Dermatitis, Psoriasis, HS

More than 60% of patients with psoriasis achieved PASI 100 at week 16 with bimekizumab and maintained skin clearance up to 4 Years.

Bimekizumab Shows Long-Term Psoriasis Skin Clearance in 4-Year Phase 3 Data

This analysis highlights the risk of superficial fungal infections among patients with moderate-to-severe psoriasis given biologics such as IL-17 inhibitors.

Biologic Use in Psoriasis Raises Risk of Superficial Fungal Infection Among Patients

This analysis highlights the observed risk of developing psoriasis when using dupilumab to treat atopic dermatitis.

Dupilumab-Treated Patients with Atopic Dermatitis at Increased Risk of Psoriasis

Recent research comparing the two diseases against a sample of the general population has indicated a substantially higher mortality risk and rate in GPP than in plaque psoriasis.

Generalized Pustular Psoriasis May Have Higher Mortality than Plaque Psoriasis

Study findings highlight a heightened risk of MetS in patients with psoriasis, especially those with more severe disease based on PASI scores.

Psoriasis Linked to Increased Metabolic Syndrome Risk, Mediated by Disease Activity

Research has indicated a suggestive association between predicted psoriasis and uterine corpus cancer in women and prostate cancer in men.

Psoriasis May Be a Protective Factor for Certain Forms of Cancer, Research Suggests

In this interview with Milaan Shah, MD, the expert consensus panel reviewing deucravacitinib’s safety and efficacy for psoriasis is discussed.

Efficacy, Safety of Deucravacitinib for Psoriasis, with Milaan Shah, MD

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.